{"commentary":{"count":44,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":38,"youtube":3,"podcast":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05535218\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"SURE-02","nct_id":"NCT05535218","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=sure-02-nct05535218. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"SURE-02","arms":[{"description":"Single Arm treatment","label":"Single Arm","type":"OTHER"}],"collaborators":[],"completion_date":{"date":"2027-02","type":"ESTIMATED"},"conditions":["Muscle-invasive Urothelial Carcinoma of the Bladder"],"enrollment":{"count":48,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Sacituzumab govitecan is a humanized mAb with a hydrolysable linker through which SN-38 is conjugated to the humanized mAb hRS7 IgG1κ to enhance the delivery of SN-38 to Trop-2- expressing tumors, whi","type":"DRUG"}],"last_update":"2025-04-02","lead_sponsor":"Claudia Guerrieri","official_title":"SURE-02_An Open Label, Single-arm, Phase 2 Study of Perioperative Pembrolizumab Plus Sacituzumab Govitecan, and Bladder-saving Approach, for Patients With Muscle-invasive Bladder Cancer Who Cannot Receive or Refuse Cisplatin-based Chemotherapy","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-02","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Clinical CR-rate","timeFrame":"36 months"}],"references":[{"citation":"Necchi A, Maiorano BA, de Jong JJ, Proudfoot JA, Basile G, Cigliola A, Mercinelli C, Tateo V, Piacentini M, Pastorino G, Latini G, Tomasi E, Davicioni E, Moschini M, Brembilla G, Colecchia M, de Cobelli F, Briganti A, Ross JS, Pavlick DC, Montorsi F. Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study. Lancet Oncol. 2026 Apr;27(4):442-451. doi: 10.1016/S1470-2045(26)00050-1. Epub 2026 Feb 27.","pmid":"41771275","type":"DERIVED"}],"start_date":{"date":"2023-09-20","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Pembrolizumab-Sacituzumab Govitecan Combination to Treat High-risk, Localized Bladder Cancer","url":"https://clinicaltrials.gov/study/NCT05535218"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/sure-02-nct05535218"}